The novel coronavirus outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was recognized in late 2019 in Wuhan, China . Subsequently, the World Health Organization declared coronavirus disease 2019 (COVID-19) as a pandemic on 11 March 2020 . The proportion of potentially fatal coronavirus infections may vary by location, age, and underlying risk factors . However, acute respiratory distress syndrome (ARDS) is the most frequent complication and leading cause of death in critically ill patients . Immunomodulatory and anti-inflammatory agents have received great attention as therapeutic strategies against COVID-19 . Here, we review potential mechanisms and special clinical considerations of supplementation with curcumin as an anti-inflammatory and antioxidant compound in the setting of COVID-19 clinical research.